Will Pradaxa catch up with launching it as reversal agent?

Novel oral anticoagulants(NOAC) have started to be ranked in a year after they were applied for the National Health Insurance as the primary treatment for stroke prevention in treating stroke and embolism for atrial fibrillation(SPAF) patients.

While ‘Xarelto(generic name: rivaroxaban)’ was aggregated to lead in the total prescriptions and the SPAF indication category among NOACs, ‘Pradaxa(gen...